The one-ring open hydrolysis product intermediates of the cardioprotective agent ICRF-187 (dexrazoxane) displace iron from iron-anthracycline complexes
- 1 September 1993
- journal article
- Published by Springer Nature in Inflammation Research
- Vol. 40 (1-2), 86-95
- https://doi.org/10.1007/bf01976756
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Pharmacodynamics of the Hydrolysis-Activation of the Cardioprotective Agent (+)-1,2-Bis(3,5-dioxopiperazinyl-1-yl)propaneJournal of Pharmaceutical Sciences, 1994
- Characterization of the Aqueous Decomposition Products of (+)1,2-bis(3,5-Dioxopiperazinyl-1-yl)-propane (ICRF-187) by Liquid Chromatographic and Mass Spectral AnalysisJournal of Pharmaceutical Sciences, 1991
- Cardioxane—ICRF-187 towards anticancer drug specificity through selective toxicity reductionCancer Treatment Reviews, 1991
- Copper(II) complexes of hydrolysis products of the anticancer bis(3,5-dioxopiperazin-1-yl)alkanes. Displacement of co-ordinated carboxylate ligands by deprotonated amide groups in basic solutionJ. Chem. Soc., Dalton Trans., 1991
- Oxyradical production results from the Fe3+–doxorubicin complex undergoing self-reduction by its α-ketol groupBiochemistry and Cell Biology, 1990
- The iron(III) and copper(II) complexes of adriamycin promote the hydrolysis of the cardioprotective agent ICRF-187 ((+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane)Inflammation Research, 1990
- The interaction of the cardioprotective agent ICRF-187 ((+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane); its hydrolysis product (ICRF-198); and other chelating agents with the Fe(III) and Cu(II) complexes of adriamycinInflammation Research, 1989
- Protective Effect of the Bispiperazinedione ICRF-187 against Doxorubicin-Induced Cardiac Toxicity in Women with Advanced Breast CancerNew England Journal of Medicine, 1988
- Stereochemistry of the antitumor agent 4,4'-(1,2-propanediyl)bis(4-piperazine-2,6-dione): crystal and molecular structures of the racemate (ICRF-159) and a soluble enantiomer (ICRF-187)Journal of the American Chemical Society, 1982
- Metal binding by pharmaceuticals. part 2. interactions of Ca(II), Cu(II), Fe(II), Mg(II), Mn(II) and Zn(II) with the intracellular hydrolysis products of the antitumour agent ICRF 159 and its inactive homologue ICRF 192Inflammation Research, 1982